Share Price:

APNASPENAspen Pharmacare Hldgs155950 (0.00%)
Our Response to Covid
Country Sites

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

Author: bpc

Aspen increases revenue by 33 percent

Aspen increases revenue by 33 percent. Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited (Apn), Africa’s largest pharmaceutical manufacturer, has announced pleasing results for the interim period ended 31 December 2010. Group Performance: Headline earnings from continuing operations increased by 35 percent to R1.147 billion. Revenue from continuing operations rose by 33 percent to R5.990 billion (R4.519 billion). Operating profit from continuing operations improved by 28 percent to R1.614 billion (R1.260 billion). Headline earnings per share (HEPS) from continuing operations increased by 15 percent to 265.3 cents (230.8 cents). The rise in headline earnings per share was diluted by an increase in the weighted average number of shares in issue as a consequence of the issue of shares on 1 December 2009 in settlement of the transaction with GlaxoSmithKline (“GSK”) concluded on that date. Stephen Saad, Aspen Group Chief Executive said, “The South African pharmaceutical division’s consistently good performance ensured that Aspen retained it position as the leader in the South African pharmaceutical market. The successful integration of the GSK business has further contributed and Aspen is now also ranked first in the branded product segment. Aspen’s international and sub-Saharan Africa businesses also performed well, delivering increased revenue and operating profit across the Group”. South African Business The South African business increased revenue by 29% to R3.300 billion and improved operating profit by 23% to R0.996 billion. The pharmaceutical division led the growth in revenue raising sales by 36% to R2.682 billion. Consumer division sales were up 8% to R0.618 billion. Profit margins benefited from production efficiencies, procurement savings and the strength of the Rand. The higher insurance compensation received in the prior period inflated the comparative profit margin for that period. The pharmaceutical business grew ahead of the market in the private sector, increasing Aspen’s share as measured by IMS to 16.7%. Sales of the GSK products for the six months to 31 December 2010 were R463 million against R53 million from one month of sales in the prior period. In the recently adjudicated anti-retroviral (“ARV”) tender, Aspen was awarded 41% by value of the anticipated ARV requirements of the South African government over a two-year period. This validates the cost competitiveness of the Group’s production capabilities. There has been ongoing investment in the manufacturing capabilities of the Group in South Africa. Most capital projects are well advanced. The focus of these projects has been adding capacity, enhancing technical standards and improving efficiency. Sub-Saharan Africa Business Revenue in the sub-Saharan Africa business more than doubled from R279 million to R666 million due to the full period contribution from the GSK Aspen Healthcare for Africa collaboration. Operating profit followed a similar trend, growing from R41 million to R119 million. Performance at Shelys, Aspen’s 60% owned subsidiary in East Africa, improved on the unsatisfactory showing in the second half of the 2010 financial year. International Business The international business increased revenue by 39% to R2.423 billion. Revenue benefited by R600 million (2009: R108 million) from the inclusion of the brands and the German-based Bad Oldesloe production facility acquired from GSK in December 2009 for the full period. Asia Pacific revenue was up 28% to R957 million, Latin America revenue increased 20% to R599 million and revenue in the Rest of the World region rose 76% to R867 million. Operating profit before amortisation and once-off items was up 27% to R551 million. The AUD 900 million (approximately R6.3 billion) acquisition of the pharmaceutical business of Sigma, Australia’s largest listed pharmaceutical company, completed on 31 January 2011. Integration of this business with Aspen Australia is well underway and is progressing to plan. Prospects The South African pharmaceutical business has strengthened its position as the market leader over the past period. Performance in the second half of the year will however be affected by the reduced value of the recent ARV tender award. The Minister of Health has announced that no consideration will be given to an increase in the Single Exit Price before the end of 2011. The South African consumer business will be adversely affected by the ending in April 2011 of the Pfizer infant milk license agreement, which generated annual sales of approximately R250 million. Pfizer has taken the decision to enter the South African market itself following the acquisition of the infant milk franchise as part of its take-over of Wyeth. Aspen has expanded its own infant milk offering with the introduction of the Infacare Gold range in order to replace the Pfizer brands. The sub-Saharan Africa business is on a firm footing and the positive performance of the first half of the year should be maintained in the second half. The Asia Pacific region of the International business is set for strong growth as the Sigma pharmaceutical business is integrated into Aspen Australia. The earnings per share impact for this financial year is likely to be close to neutral due to the expensing of transaction fees, stamp duties and restructuring costs expected to exceed R100 million. In years thereafter the transaction is anticipated to be earnings accretive as synergistic benefits are realised. The International business will continue to transition products acquired from GSK to the Aspen global distribution network. Once complete, the Group will be well positioned to realise procurement and marketing opportunities with these brands. The Group remains well placed for growth into the medium term. The launch of new products from the extensive product pipeline will provide organic growth across all major markets. The expanded business in the Asia Pacific region is expected to provide further growth momentum. Latin America remains a core focus area for the Group as a region with great potential. Opportunities to add to the portfolio of global brands will be actively pursued. ends Issued by: Shauneen Beukes, SBC Tel: +27 (012) 661-8467 : Cell: +27 82 389 8900 On Behalf Of: Stephen Saad, Aspen Group Chief Executive Tel: +27 (031) 580-8603 Gus Attridge, Aspen Deputy Group Chief Executive Tel: +27 (031) 580-8605 Roshni Gajjar, Aspen Investor Relations Tel: +27 (031)… Continue reading Aspen increases revenue by 33 percent

FM’s Nine Questions to Stephen Saad

Nine questions – Stephen Saad Group Chief Executive, Aspen Pharmacare Holdings Limited Xolile Bhengu Thursday, 24 Feb 2011 2011 started off with finalising the Sigma Pharmaceuticals deal for R6,1bn. What does the acquisition mean for Aspen? The Sigma acquisition presents synergies for the extension of our existing branded products in Australia, with the addition of Sigma’s current consumer portfolios. We are already seeing savings around procurement costs and creating a foundation for further development of Aspen’s business in the Asia Pacific region. Do you plan to make a bid for the total Sigma business? Initially we did, but we decided against buying the wholesale business in the end. It is imperative to have a relationship with an existing and established supplier for the distribution of generic products in Australia. We decided to buy only the pharmaceutical business and focus on our level of expertise. Why is the Asia Pacific market key to your expansion plans? Our growth strategy focuses on realising opportunities in emerging markets, and Asia Pacific is a growing economy with demand for good quality products. Once our own sales teams have been established in Australia, with its proximity to Southeast Asia making it an ideal base, we’ll be able to leverage our product pipeline into Southeast Asia. Are you planning any further partnerships or acquisitions in Asia Pacific? We have spoken to some companies in the region as part of our partnering model and strategy. Our primary aim though is to take control and develop our marketing and sales functions. Aspen Australia has achieved double- digit growth since its 2001 inception. What has driven this success? We have an excellent management team, which is the same team that started the business in 2001, supported by experienced sales representatives. We also focus on niche market opportunities, and never compete in areas where we don’t show strength. The team also employs strategies like hiring retired experienced staff who already know the business and the market. Your company and some of your competitors took a knock from the withdrawal of painkillers containing dextropropoxyphene. Are you concerned about future drug withdrawals as a result of foreign legislation? The impact of the withdrawal on Aspen’s business was only R4m/year revenue. We had similar experiences with the withdrawal of phenolphthalein in our laxatives that have been reformulated and the rescheduling of pseudoephedrine in Sinuclear a few years ago. Most of the products that are at risk of being withdrawn have already been addressed and our regulatory team monitors legislation. The risk is the potential abuse of medicines, such as the SA experience of ARVs being used as a narcotic. Aspen is a significant stakeholder in government’s ARV tender, with a 40,6% stake. Will Aspen pass down the 300% reduction in ARV input costs to consumers? The biggest decrease for ARVs came from the reduced costs of active pharmaceutical ingredients (APIs), and the inclusion of generics on the tender further reduced pricing. However, for other Aspen products APIs are only a small component of costs. Consumers will benefit more from the launch of more affordable generic medicines. In addition, pricing in the private sector is regulated via the single exit price (SEP) mechanism and we are able to supply at that price. We don’t foresee an SEP increase this year. As a supplier of branded and generic pharmaceuticals in 100 countries, where do you predict the strongest growth this year? Apart from the Asia Pacific region we want to increase our footprint in Latin America. SA and Australia have the most settled businesses with a solid base turnover and opportunities for growth. Why should investors invest in your company? For 12 years we have delivered compound annual revenue growth of 52%, operating profit of 56% and headline EPS of 49%, and we still have fantastic growth drivers . It’s a company that has performed for its shareholders.

Aspen granted generic license for the manufacture and supply of TMC278

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for those who have previous ARV treatment experience. “This agreement further strengthens Aspen’s close working relationship with Tibotec in the supply of ARV’s and will further expand Aspen’s already extensive portfolio of HIV/AIDS medicines, thereby providing patients and physicians with increased clinical options”, said Stavros Nicolaou, Aspen Senior Executive. “TMC 278 is being viewed as a compound with a number of potential benefits over existing treatments and is set to play an important role in the future management of HIV and AIDS. It is well tolerated, has a long half-life and allows once-daily dosing.” The agreement entitles Aspen to manufacture TMC278 25 mg and to market TMC278 throughout sub-Saharan Africa (“SSA”), including South Africa. Fixed-dose combinations are, in certain instances, preferred by public health treatment programs and contain multiple molecules formulated into a single tablet to ease dosage management for patients. Tibotec has chosen to collaborate with select manufacturers in order to increase access to a sustainable supply of TMC278 in areas of high HIV/AIDS prevalence.

Aspen acquires Sigma’s pharmaceutical business for R6,1 billion

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”). The acquisition was approved following the extraordinary meeting of Sigma shareholders held on 14 January 2011. The effective date of change of ownership is 31 January 2011 and will position Aspen as the leading pharmaceutical company in Australia by volume of scripts generated. Stephen Saad, Aspen’s Group Chief Executive, said “Aspen is excited about this acquisition which enables the Group to accelerate growth in its Australian business and also to stimulate expansion plans into the broader Asia Pacific region. Aspen has already demonstrated its ability to supply high quality products at competitive prices across more than 100 worldwide territories. We have confidence in our Australian management team to leverage Aspen’s world-class procurement, manufacturing and distribution capabilities to ensure the expanded Aspen business delivers growing value in Australia.” In 2010 Aspen announced that it had reached a formal agreement to acquire Sigma’s pharmaceutical business on a debt-free basis for a cash consideration of AUD 900 million. The purchase consideration is approximately ZAR 6 148 million, based on an AUD/ZAR exchange rate of 0.1464 as at 13 January 2011. The transaction was however subject to a number of conditions precedent which have now been fulfilled. The Sigma business: Sigma, which has a 98-year legacy in Australia, is listed on the Australian Securities Exchange. Sigma’s pharmaceutical business, which is now being acquired by Aspen, consists of an extensive product portfolio of branded, generic and OTC products which include many well-known and trusted Australian brands as well as five manufacturing facilities. Sigma retains its wholesale business, and is one of three major wholesaler distributors in Australia. Aspen has concluded a long-term distribution agreement with Sigma. Rationale for the acquisition of Sigma’s pharmaceutical business: Aspen Australia, established in May 2001, markets and distributes pharmaceutical and consumer products. Aspen Australia has succeeded in delivering double-digit growth since inception as a greenfields operation in 2001, and recorded revenue of approximately AUD 180 million in the year ended 30 June 2010. Aspen Australia`s success has been achieved by sound management supported by an outstanding team which has consistently built Aspen`s branded product offering and reputation in Australia. Aspen Australia is currently ranked 7th in terms of volume of Australian scripts generated and its sales representative team has been voted number one in Australia. On the basis of this successful platform, the Sigma acquisition creates the following opportunities for Aspen: The extension of Aspen’s existing branded products business in Australia with the addition of Sigma’s branded, generics and OTC portfolios; An established point of entry into the Australian generics and OTC sectors for the introduction of Aspen`s pipeline of generic and OTC products; Securing a distribution channel for generic products through Sigma’s retained wholesale division; Providing additional opportunities to launch Aspen’s prolific product pipeline; Leveraging Aspen’s global manufacturing experience, expertise and capability through an Australian-based manufacturing presence; and Creating a foundation for further development of Aspen`s business in the Asia Pacific region. Based upon the historic performance of Aspen and Sigma in the Australian market, the combination of Sigma’s pharmaceutical business with Aspen’s existing business in Australia should lead to 1 in every 8 Australian prescriptions being written for an Aspen product and result in Aspen being ranked first by volume of scripts generated in Australia. Issued By: Shauneen Beukes, Shauneen Beukes Communication Tel: +27 12 661 8467; Cell: +27 82 389 8900 On Behalf of: Stephen Saad, Aspen Group Chief Executive Tel: +27 31 580 8601 Gus Attridge, Aspen Deputy Group Chief Executive Tel: +27 31 580 8602 Roshni Gajjar, Aspen Investor Relations Tel: +27 31 580 8649; Cell: +27 82 789 1826

Aspen ARV tender bid is successful

Aspen ARV tender bid is successfulFollowing the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Aspen) has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite of strong competition. The tender is effective for a period of two years, commencing 01 January 2011. Aspen secured more than 40% of the awarded tender value based upon expected future demand as published in the invitation to tender. The tender value is estimated to be R3.6 billion over 2 years. The South African ARV Tender is the largest of its kind in the world. Aspen has been a leading supplier to this tender since inception of the programme, providing a consistent and reliable supply of high-quality ARV products to the State. Aspen was awarded a share of the following products: Product/ % Awarded to Aspen Abacavir Solution 20mg/ml 40% Efavirenz Tablets 600mg 70% Lamivudine Scored Tablets 150mg 70% Nevirapine Tablets 200mg 40% Tenofovir Tablets 300g 70% Zidovudine Tablets 300mg 40% These tender results are further testament to Aspen’s cost competitiveness against both local and foreign suppliers. Aspen’s range of ARV’s are produced at its world-class manufacturing facilities in Port Elizabeth, South Africa. The Group has invested more than R2 billion over the last five years in extending its manufacturing capability and enhancing the existing facilities. This has resulted in unlocking capacity to accommodate growing demand from Aspen’s domestic and foreign territories and also contributed towards further optimising manufacturing efficiencies. In his response to the ARV Tender results, Aspen Group Chief Executive, Stephen Saad said: “These tender results confirm Aspen’s cost competitiveness and its credibility as a reliable supplier of pharmaceutical products. Aspen is proud to be able to contribute towards increasing access to affordable, high quality medicines in South Africa and thereby assist in the treatment of the HIV/AIDS pandemic.” Aspen’s portfolio of ARV’s supports close to 900 000 patients in South Africa daily. 14 December 2010 Sponsor: Investec Bank Limited Date: 14/12/2010 11:48:15 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Aspen’s CSI programmes provide increased ARV access to mothers and infants

Aspen’s CSI programmes provide increased ARV access to mothers and infants Johannesburg. Aspen Pharmacare, South Africa’s leading pharmaceutical manufacturer, as part of its continued social commitment programme has established an antiretroviral (“ARV”) dispensary and has contributed to the upgrading of critical theatre equipment at the Rahima Moosa Mother and Child Hospital (“RMMCH”) in Coronationville. Stavros Nicolaou, Aspen Pharmacare’s Senior Executive, Strategic Trade Development said “The establishment of the ARV dispensary at the RMMCH makes a meaningful difference to both HIV infected mothers and their babies who would otherwise have limited access to life saving ARV treatment. There is a notable pediatric shortage of public sector ARV treatment. This social investment provides HIV positive mothers and their babies who are born and treated at RMMCH with the hope of living a relatively normal, healthy life.” Chief Operating Officer of Gauteng Health, Dr Abdul Rahman said “RMMCH has a large maternal unit which was in desperate need of pediatric access to ARV treatment for infants and toddlers. ”Aspen has proven to be a reliable partner when we have needed Corporate Social assistance”. Nicolaou said, “This contribution forms part of Aspen’s ongoing CSI commitment towards assisting in addressing the shortages of primary healthcare and SA’s public health challenges in general. Aspen’s focus of alleviating the plight of HIV/AIDS and Tuberculosis infected patients, remains core to our CSI initiatives. South Africa has one of the highest maternal and infant mortality rates which is regrettably in line with that of some of the least develop countries. We have an obligation as a responsible corporate citizen to assist in public health challenges and to endeavor to make a difference in the lives of disadvantaged communities. We have been delivering on this responsibility and on our commitment to the people of South Africa for more than a decade”. Aspen’s most significant CSI accomplishments include, among others, the construction and improvement of seven healthcare facilities in previously disadvantaged communities. The supported clinics are able to provide a broad range of primary healthcare services, including the treatment of acute conditions, the provision of HIV/Aids services, the supply of prescribed medication, healthcare awareness training session and HIV/AIDS and tuberculosis management programmes. L-R: Dr Abdul Rahman, Chief Operating Officer of Gauteng Health, Dr Edward Hand, Clinical Manager Rahima Moosa Clinic, Stavros Nicolaou, Aspen Pharmacare – Senior Executive Strategic Trade Development, Jackie Tau, Aspen Pharmacare – CSI Manager.

Aspen’s Revenue increases by 20% to exceed R10 billion

Johannesburg – JSE Ltd listed Aspen Pharmacare Holdings Limited, Africa’s largest pharmaceutical manufacturer, has produced excellent results for the year ended 30 June 2010. The South African business was the leading driver of the growth achieved. GROUP PERFORMANCE: Group revenue increased by 20% to R10.147 billion (R8.441 billion). Group operating profit improved by 20% to R2.615 billion (R2.175 billion). Group headline earnings rose 39% to R1.941 billion (R1.394 billion). Group headline earnings per share (HEPS) grew by 24% to 482.9 cents (389.4 cents). Group earnings per share increased by 32% to 494.9 as a consequence of a capital profit on the sale of Onco Therapies. A capital distribution of 70 cents per ordinary share (zero) by way of a capital reduction has been declared. Stephen Saad, Aspen Group Chief Executive said, “The South African business delivered pleasing results and retained its position as the market leader in the pharmaceutical sector. Ongoing organic growth was instrumental in Aspen maintaining its position as the leading supplier of pharmaceuticals to both the private and public sectors in South Africa. The Group’s international business continued to perform well and all of the strategic investments undertaken with GlaxoSmithKline (“GSK”) have bedded down well. COMPLETION OF THE GSK TRANSACTIONS With effect from 1 December 2009, Aspen completed a series of strategic, interdependent transactions with GSK (“the GSK transactions”) which had been announced on 12 May 2009. The GSK transactions comprise: The acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa; The formation of a collaboration agreement between Aspen and GSK in relation to the marketing and selling of prescription pharmaceuticals in sub-Saharan Africa; The acquisition by Aspen Global of eight specialist branded products (Alkeran, Leukeran, Purinethol, Kemadrin, Lanvis, Myleran, Septrin and Trandate) for worldwide distribution; The acquisition of GSK’s manufacturing facility in Bad Oldesloe, Germany; and The issue by Aspen of 68.5 million ordinary shares to GSK at R66.80 per share amounting to a total value of R4.576 billion. SOUTH AFRICAN BUSINESS Revenue from the South African business increased 31% to R5.652 billion. The pharmaceutical division raised revenue from domestic brands by 40% to R4.391 billion and the consumer division increased revenue by 5% to R1.161 billion. Operating profit increased from R1.045 billion to R1.588 billion. Profit margins recovered after the contractions of the previous two years due to improved production efficiencies and procurement savings supported by a stronger Rand, which lowered the cost of imported materials. The integration of GSK’s South African pharmaceutical business was successfully executed and has immediately yielded positive results reflected in an increase in share of the branded products sector. Growth in consumer revenue was achieved in a sluggish retail sector battling to emerge from the recession. Performance was also negatively affected by an interruption in the supply of infant milk formula due to the explosion at the Nutritionals manufacturing facility last year. Insurance compensation of R162 million was received during the year, covering the consequent loss of profits and the restoration of the facility, and has been reported under “other operating income”. SUB-SAHARAN AFRICA BUSINESS Revenue for the sub-Saharan African business declined 2% to R910 million and operating profits decreased from R173 million to R66 million. The GSK Aspen Healthcare for Africa collaboration commenced on 1 December 2009 and met all performance expectations. Aspen has established a separate management and reporting structure for the sub-Saharan Africa business. Included in this business segment are exports into sub-Saharan Africa from South Africa, the Shelys Africa business based in East Africa and the GSK Aspen Healthcare for Africa collaboration. INTERNATIONAL BUSINESS The international business increased revenue by 27% to R4.053 billion whilst operating profit before amortisation and impairments was 10% higher at R1.114 billion. Operating profit was diluted by the reduced contribution from the Latin American (“Latam”) operations and the reduction in profits resulting from the transition of the Global Brands to the Aspen distribution network. Revenue from Global Brands grew by 33% to R2.008 billion. Eltroxin, Lanoxin, Imuran and Zyloric, the four Global Brands acquired from GSK with effect from 30 June 2008, comprise the greatest portion of this revenue. These four Global Brands were largely transitioned to the Aspen distribution network during the course of the year and achieved double digit revenue growth in US dollars. The balance of the growth in the Global Brands came from the products added to this portfolio during the year. The Asia Pacific domestic brands increased revenue by 11% to R1.016 billion. This was achieved despite regulated price reductions in Australia, the most material territory in this region. Revenue from domestic brands in Latam declined by 3% to R813 million. However, the successful implementation of a restructuring plan in the Brazilian business resulted in improved revenue growth of 8% during the second half of the year. As part of the reshaping of the Brazilian operation, agreement was reached to sell the Campos manufacturing facility and related products to Strides Arcolab (“Strides”). The Group also restructured its oncology arrangements with Strides. Aspen has entered into agreements to sell its interest in the Onco Therapies and Onco Laboratories joint ventures to Strides for USD 117 million. Aspen has in turn secured a license for existing and future oncology products from Strides in specified territories. The sale of Onco Therapies was completed prior to 30 June 2010, giving rise to a profit on disposal of R155 million. Conditions precedent relating to the sale of Onco Laboratories remain to be fulfilled, completion being expected during the year ahead. The Onco Laboratories assets have been classified as “held for sale”. PROPOSED ACQUISITION OF THE SIGMA PHARMACEUTICAL BUSINESS On 16 August 2010, Aspen announced that the board of directors of Sigma Pharmaceuticals Limited (“Sigma”) had agreed to support an offer by Aspen to acquire the pharmaceutical business conducted by Sigma (“Sigma pharmaceutical business”) for a cash consideration AUD 900 million. Completion of this transaction is conditional upon, inter alia, requisite regulatory approval and the approval of Sigma shareholders. Work is ongoing on the fulfillment of these conditions.… Continue reading Aspen’s Revenue increases by 20% to exceed R10 billion

Aspen Trading Update

By : Shauneen Beukes APN – Aspen Pharmacare Holdings Limited – Trading update Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN & ISIN: ZAE000066692 (“Aspen”) Trading update Aspen shareholders are hereby advised that headline earnings per share, for the 12 months ended 30 June 2010, are expected to exceed those reported in the comparative period, ended 30 June 2009, by 20% to 25%. Earnings per share are anticipated to exceed those of the comparative period by 30% to 35%. The lower increase in headline earnings per share is caused by the exclusion of non-recurring capital profits and losses in the determination thereof. The Group’s South African business has been the leading contributor to the growth recorded. The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen`s external auditors. Aspen`s results are scheduled to be published on SENS on 15 September 2010. Woodmead 23 August 2010 Sponsor Investec Bank Limited

Closed Period

Aspen is in a closed period from 1st January 2026 until the publication of the interim results on the JSE SENS platform on the 3rd March 2026.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.

Corporate

Our career opportunities are across the corporate spectrum, including Human Capital, Digital Technology, Legal, and Risk & Sustainability. Our employees are given the opportunity to hone their skills and develop the experience of excellence in their chosen field in the pharmaceutical industry.

View our teams below:

Human Capital
Legal

Supply Chain

Treasury
Ethics & Compliance
Risk & Sustainability
Digital Technology

Tax